#USA #CAR T-cell Therapy #Eurofins Viracor #Lenexa #ExPeCT™

Introduction

In the dynamic landscape of clinical diagnostics, Eurofins Viracor has taken a significant step forward with the introduction of their latest innovation, the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay. This advanced assay is tailored to enable healthcare professionals to monitor the performance of CAR T-cell therapies with remarkable precision and speed.

What is the ExPeCT™ Assay?

The ExPeCT™ assay is a specialized tool designed for tracking the expansion and persistence of CAR T-cells specifically targeting the CD19 antigen. This assay is particularly focused on the second-generation CAR T-cell therapy known as obecabtagene autoleucel (obe-cel). It delivers non-invasive blood test results within approximately 24 hours of sample receipt, allowing clinicians to make informed decisions about therapy adjustments in a timely manner.

The Importance of Monitoring CAR T-Cell Therapy

CAR T-cell therapy represents a groundbreaking advancement in treatment options for various hematological malignancies. However, its success heavily relies on continuous monitoring of the patient’s response to the treatment. The ExPeCT™ assay provides real-time insights into patient-specific responses, enabling healthcare teams to swiftly adapt treatment plans based on the assay's findings. This proactive monitoring can significantly enhance patient outcomes by ensuring that any potential issues are addressed promptly.

Features and Benefits of ExPeCT™

1. Real-Time Monitoring: The assay allows for immediate feedback on CAR T-cell levels, helping clinicians to gauge the effectiveness of therapy swiftly.

2. Quick Turnaround Time: With results delivered in around 24 hours, healthcare providers can make timely interventions, ultimately improving patient care.

3. Non-Invasive Testing: By utilizing a blood sample for testing, the ExPeCT™ assay minimizes discomfort for patients compared to more invasive testing methods.

4. Customized for Obe-cel: The assay's development was guided by extensive research and focuses specifically on the performance of obe-cel, ensuring relevance and accuracy.

Eurofins Viracor's Commitment to Quality

With over four decades of expertise in clinical diagnostics, Eurofins Viracor is dedicated to providing reliable and actionable results to improve patient care. Their commitment is reflected in their innovative product offerings, such as the ExPeCT™ assay. The team at Eurofins continuously strives to bridge the gap between diagnostic testing and patient health, ensuring that each assay directly contributes to enhancing treatment decisions.

How to Access the ExPeCT™ Assay

Healthcare professionals interested in utilizing the ExPeCT™ anti-CD19 CAR T-cell assay can find more information on Eurofins Viracor's official website. They offer comprehensive insights into the assay's applications and support to facilitate seamless integration into clinical practices.

For detailed enquiries, the Client Services team can be reached at (800) 305-5198, ensuring that healthcare providers receive the necessary support for implementing this advanced tool in their treatment protocols.

Conclusion

The launch of the ExPeCT™ anti-CD19 CAR T-cell assay marks a notable advancement in the field of immunotherapy, providing clinicians with the ability to monitor CAR T-cell therapies like never before. As more healthcare professionals adopt such innovative testing solutions, the future of cancer treatment looks increasingly promising, with Eurofins Viracor leading the way in clinical diagnostics.

For more information, please visit https://www.eurofins-viracor.com/our-testing/immunology/.